Browse studies, page 714
Page 714 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Hepatic restorative potential of Portulaca oleracea ethanolic extract and/or metformin in type II diabetes mellitus model induced by high-fat diet and STZ Journal of Basic and Applied Zoology, 2025
- Red, green, and blue model assessment and AQbD approach to HPTLC method for concomitant analysis of metformin, pioglitazone, and teneligliptin Future Journal of Pharmaceutical Sciences, 2024
- Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin Journal of the American Society of Nephrology, 2020
- Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK Diabetes Therapy, 2020
- Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson’s disease Frontiers in Neuroscience, 2024
- Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model Pathophysiology, 2024
- Abstract P162: Comparison Of The Clinical Effect Of Empagliflozin On Glycemic And Non-glycemic Parameters In Japanese Patients With Type 2 Diabetes And Cardiovascular Disease Treated With Or Without Baseline Metformin Hypertension, 2021
- 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes Artery Research, 2019
- Once-Weekly Semaglutide 1 mg vs Empagliflozin 25 mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: a Meta-Regression Analysis of Individual Patient Data Diabetologie und Stoffwechsel, 2022
- Combination of metformin and empagliflozin CAN changes GUT microbiota of type 2 diabetic patients with hypothyroidism and coronary artery disease SCIENTIFIC PRACTICE: MODERN AND CLASSICAL RESEARCH METHODS, 2022
- Lipid metabolism features in patients with type 2 diabetes on combination therapy with empagliflozin compared with metformin monotherapy Endocrinology News Opinions Training, 2024
- Comparative Study between combination therapy Empagliflozin–Sitagliptin and Empagliflozin–Alogliptin in addition to Metformin assessing the hypoglycemic effect on patients diagnosed with malignancy and poorly controlled Type 2 diabetes mellitus as comorbidity Journal of Carcinogenesis, 2025
- Efficacy and safety of addition of empagliflozin in diabetic patients uncontrolled with glimepiride + metformin + teneligliptin Journal of Evidence Based Medicine and Healthcare, 2018
- Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes Diabetologie und Stoffwechsel, 2015
- Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study Diabetes Therapy, 2023
- 1223-P: Empagliflozin vs. Dapagliflozin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin, Glimepiride, and Dipeptidyl Peptide-4 Inhibitors: A 52-Week Prospective Observational Study Diabetes, 2019
- SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients Journal of the Endocrine Society, 2019
- Observational Study to Evaluate Effectiveness of Adding Empagliflozin to Uncontrolled Type 2 Diabetes Patients Who Were Uncontrolled On Metformin Rather Than Up Titrating the Metformin Dose 2020
- MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D Journal of the Endocrine Society, 2020
- Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients Iraqi Journal of Pharmaceutical Sciences, 2024
- Linagliptin as add‐on to empagliflozin and metformin in patients with type 2 diabetes: Two 24‐week randomized, double‐blind, double‐dummy, parallel‐group trials Diabetes, obesity and metabolism, 2017
- 1148-P: Antioxidative Effects of Empagliflozin and Metformin in Type 1 Diabetes Mellitus Patients Diabetes, 2020
- Effect of a 12-month treatment with liraglutide, empagliflozin and their combination on carotid intima-media thickness in patients with type 2 diabetes mellitus European Heart Journal, 2025
- The effect of empagliflozin on fractalkine levels in patients with type 2 diabetes mellitus Clinical endocrinology and endocrine surgery, 2025
- Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients with Type 2 Diabetes Mellitus Endocrine Practice, 2021
- Developing Pharmacological Therapies for Atrial Fibrillation Targeting Mitochondrial Dysfunction and Oxidative Stress: A Scoping Review International journal of molecular sciences, 2023
- Systemic impacts of diabetes on spermatogenesis and intervention strategies: multilayered mechanism analysis and cutting-edge therapeutic approaches Reproductive biology and endocrinology : RB&E, 2025
- An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury Drug safety, 2025
- Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?-A Review of Intervention Studies Nutrients, 2022
- Cardiorenal Syndrome: Molecular Pathways Linking Cardiovascular Dysfunction and Chronic Kidney Disease Progression International journal of molecular sciences, 2025
- New-Onset Diabetes Mellitus in Post-renal Transplant Patients on Tacrolimus and Mycophenolate: A Systematic Review Cureus, 2022
- Comparative effectiveness of acupuncture and pharmacological interventions in treating diabetic stroke: A protocol for a systematic review and network meta-analysis Medicine, 2022
- Present and Future Perspectives in the Treatment of Liver Fibrosis Pharmaceuticals (Basel, Switzerland), 2025
- Analysis of Reports Sent to the Portuguese Pharmacovigilance System and Published Literature Regarding the Safety of Metformin in the Elderly Healthcare (Basel, Switzerland), 2023
- Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM Biomolecules, 2025
- A review on herbal interventions and nanotechnological advancements for managing polycystic ovarian syndrome JBRA assisted reproduction, 2025
- A Structured Narrative Review of the OSA-T2DM Axis Journal of clinical medicine, 2025
- Potentials of Natural Antioxidants in Reducing Inflammation and Oxidative Stress in Chronic Kidney Disease Antioxidants (Basel, Switzerland), 2024
- The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction Cardiovascular diabetology, 2023
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention International journal of molecular sciences, 2025
- Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy International journal of molecular sciences, 2025
- Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists Pharmaceutics, 2026
- Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis Journal of Clinical Medicine, 2019
- Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis Diabetes Therapy, 2018
- Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials Diabetology & Metabolic Syndrome, 2025
- Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetic Nephropathy: A Review of Clinical Effectiveness Europe PMC (PubMed Central), 2019
- Sodium-glucose Co-transporter 2 Inhibitors for the Treatment of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Europe PMC (PubMed Central), 2019
- Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials International Journal of Endocrinology, 2020
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes—A Systematic Review Journal of Personalized Medicine, 2025
- Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review Chinese Medical Journal, 2023
- Anorectic drugs: an experimental and clinical perspective A Review Journal of Complementary Medicine Research, 2020
- Effect of antidiabetic drugs on gut endocrine function after metabolic and bariatric surgery: a systematic review Obesity and Endocrinology, 2025
- Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis Diabetes Therapy, 2020
- Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin Dove Medical Press (Taylor and Francis Group), 2016
- Comparison of Efficacy of Dipeptidyl Peptidase-4-Inhibitor Versus Sulfonylureas in Type 2 Diabetes Patients Inadequately Controlled with Metformin; A Narrative Review Indian Journal of Public Health Research & Development, 2020
- Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Drug Research, 2021
- Efficacy Of Ertugliflozin Compared With Metformin Or Placebo In Reducing Hba1c Levels Among Adults With Type 2 Diabetes: A Systematic Review And Meta-Analysis Devotion Journal of Research and Community Service, 2025
- Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis Journal of Clinical Medicine, 2022
- Cardioprotective Effects of Antidiabetic Medications in Type 2 Diabetes - Mechanisms and Clinical Outcomes: A Narrative Review Archives of Pharmaceutical Sciences Ain Shams University, 2025
- Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis Archives of Endocrinology and Metabolism, 2019
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis Endocrine Journal, 2018
- A Systematic Review: Cost-Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors as Add-on to Metformin JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA, 2025
- Metformin and type 2 diabetes in the era of cardiovascular outcome trials; A narrative review Journal of Atherosclerosis Prevention and Treatment, 2022
- Immunomodulatory Effects of SGLT2 Inhibitors and Metformin in Managing Rheumatic Diseases: A Narrative Review Mediterranean Journal of Rheumatology, 2024
- Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers Current Opinion in Pharmacology, 2021
- Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review Kidney Medicine, 2025
- Effect of empagliflozin on liver function in type 2 diabetes: A systematic review and meta-analysis of randomized trials Journal of Current Biomedical Reports, 2023
- A Narrative Review: Repurposing Metformin as a Potential Therapeutic Agent for Oral Cancer Cancers, 2024
- On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects? Ageing Research Reviews, 2023
- Network meta-analysis of responses to DPP-4 and SGLT2 inhibitors: What next after metformin with a baseline HbA1c ≤8%? 2017
- Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden Toxicology reports, 2026
- Patient Adherence for Oral Combination Therapies in Diabetes Management: A Scoping Review Health science reports, 2025
- Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies iScience, 2026
- Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms, Current Treatment and Therapeutic Potential of Plant Antioxidants Antioxidants (Basel, Switzerland), 2026
- Non-Coding RNA in Type 2 Diabetes Cardio-Renal Complications and SGLT2 Inhibitor Response International journal of molecular sciences, 2025
- Ceramides as Biomarkers and Pharmacological Targets in Heart Failure Pathophysiology Biomolecules, 2026
- Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy Cureus, 2026
- The gut microbiome-cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension Frontiers in endocrinology, 2026
- Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases Antioxidants (Basel, Switzerland), 2025
- Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations Cureus, 2026
- Prediabetes in children and adolescents: what do we need to know? Annals of pediatric endocrinology & metabolism, 2026
- Heart matters: How glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning Diabetes, obesity & metabolism, 2026
- Cardiometabolic Therapies Shape Non-Coding RNA Landscapes in Cardiovascular Fibrosis Metabolites, 2025
- Antidiabetic agents and male fertility: unraveling the impact of glucose-lowering therapies on sperm quality in diabetic males-a narrative review Translational andrology and urology, 2025
- Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications Journal of diabetes investigation, 2026
- Preconditioning strategies for stem cells and exosomes: Transformative potential in diabetic wound treatment: A review International journal of biological macromolecules, 2026
- Role and mechanisms of vascular smooth muscle cell phenotypic transition in diabetic macrovascular complications Biological research, 2026
- Metabolic dysfunction and the use of adjunct medications in type 1 diabetes Current opinion in endocrinology, diabetes, and obesity, 2026
- Cardiovascular diseases and heart failure in diabetes: diagnostics and management (Update 2026) Wiener klinische Wochenschrift, 2026
- Pharmacological modulation of the diabetic gut microbiome with gliflozin drugs:new insights for therapeutic targeting Journal of diabetes and metabolic disorders, 2025
- Metabolic Concepts of Sodium-Glucose Cotransporter 2 Inhibitors-Based Therapies Against Hepatocarcinogenesis and Therapy Resistance in Hepatocellular Carcinoma Life (Basel, Switzerland), 2026
- Established and emerging non-cellular therapies in inherited bone marrow failure syndromes Frontiers in immunology, 2026
- Diabetes and cancer: therapeutic implications Cardio-oncology (London, England), 2026
- Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives International journal of molecular sciences, 2026
- From Glucose Transport to Microbial Modulation: The Impact of Sodium Glucose Co-Transporter-2 Inhibitors on the Gut Microbiota Medical sciences (Basel, Switzerland), 2026
- Repurposing Antidiabetic Medications for Parkinson's Disease: Focus on Biomarker Strategies for Disease Modification International journal of molecular sciences, 2026
- Obesity in Adults with Type 1 Diabetes Mellitus Journal of obesity & metabolic syndrome, 2026
- Mitohormesis linking metabolic dysfunction and neurodegeneration: implications for dementia and therapeutic strategies Frontiers in molecular neuroscience, 2026
- The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies International journal of molecular sciences, 2026
- Breaking barriers in pulmonary health of patients with metabolic diseases: senolytics and beyond Frontiers in aging, 2026
